• Maze Therapeutics CEO Jason V. Coloma sold 1,938 shares of common stock on May 15 at USD 26 per share.
• The sales were reported as indirect holdings through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.
• Indirect holdings following the transactions were 381,073 shares in the family trust, 31,001 shares in the irrevocable trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001676170-26-000004), on May 18, 2026, and is solely responsible for the information contained therein.